Skip to main content
. Author manuscript; available in PMC: 2018 Aug 11.
Published in final edited form as: ACS Infect Dis. 2017 Jun 13;3(8):595–605. doi: 10.1021/acsinfecdis.7b00064

Table 2.

Summarization of the effect of HMOs on GBS

Donor Lewis Blood Group Antibacterial Activity Anti-biofilm activity
1 a+b− bacteriostatic (THB, THB + 1% glc) altered morphology
2 a−b+ - -
3 a−b− bacteriostatic (THB) decreased biofilm produced
4 a−b+ - -
5 a−b− - -
HHS Vulnerability Disclosure